Research and development

Specialist for Immune Sciences

Our research focus

Product pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT524) - Congenital fibrinogen deficiency
Fibrinogen (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe COVID-19
Trimodulin (BT588) - Severe community acquired pneumonia
SARS-CoV-2 Hyperimmunglobulin (CoVIg-19) (joint development CoVIg-19 Plasma Alliance) - COVID-19
Haemophilia A Therapeutic (HAT) - Haemophilia A

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine